Ask AI
Immune Targeted Therapies in ALL

CE / CME

Shaping the Future of ALL: Advancing Novel Immune-Targeted Therapies to Address Unmet Clinical Needs

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABIM MOC: maximum of 1.50 Medical Knowledge MOC points

Released: July 07, 2025

Expiration: January 06, 2026

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

In discussing the rationale for investigational T-cell engagers in the treatment of B-ALL with a colleague, which of the following statements would you say is true?

2.

How does a silent Fc domain affect safety and efficacy of investigational bispecific T-cell engagers?

3.

Which of the following findings was recently reported from the phase I/II SYRUS trial of surovatamig (AZD0486) in patients with R/R B-ALL?

4.

How confident are you in your ability to identify patients who may be eligible for ongoing clinical trials of novel immune-targeted therapies in ALL?